$MPLT News

Stifel Maintains Buy on MapLight Therapeutics, Raises Price Target to $36

HC Wainwright & Co. Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target

UBS Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $48

Craig-Hallum Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $43

MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate

HC Wainwright & Co. Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $45

MapLight Therapeutics Completes Enrollment In Its Phase 2 Zephyr Trial Evaluating Ml-007C-MA For The Treatment Of Schizophrenia

MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying

Needham Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $37

TD Cowen Initiates Coverage On MapLight Therapeutics with Buy Rating

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate

MapLight Therapeutics shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $35 price target.

MapLight Therapeutics shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $35 price target.

Canaccord Genuity Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $35

MapLight Therapeutics to Participate in Upcoming Investor Conferences

MapLight Therapeutics shares are trading lower. The company announced that it has updated the timing of its Phase 2 Schizophrenia and Autism data readouts to the third quarter of 2026.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026

MapLight Therapeutics Moves Phase 2 Schizophrenia And Autism Data Readouts To Q3 2026 As Trials Advance Faster Than Planned

MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis